To test the neuroimaging ATN biomarkers in the AD continuum, Aβ–PET SUVR (neuroimaging‐A) and tau‐PET SUVR (neuroimaging‐T) were both higher in the AD dementia compared with the CN group (p < 0.001, Figure 1G,H), whereas FDG–PET SUVR (neuroimaging‐N) was significantly lower in the AD and MCI than in the CN group (p < 0.001, Figure 1I). The gene discussed is MAPT; the disease is Alzheimer disease.